Dezima Pharma secures $18.6m for CETP inhibitor development
The company received €9.8m capital in a Series A funding round, led by Forbion Capital Partners (NL) and BioGeneration Ventures (NL), with participation from New Science Ventures (USA)
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.
Under the partnership, Crystal Pharmatech combines its expertise with Particle Sciences advanced drug delivery solutions compounds to offer clients an optimal solution for developing low solubility pharmaceutical compounds.